Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

SI-BONE Management

Management Kriterienprüfungen 3/4

SI-BONE's CEO ist Laura Francis, ernannt in Apr 2021, hat eine Amtszeit von 3.08 Jahren. Die jährliche Gesamtvergütung beträgt $3.71M, bestehend aus 16.8% Gehalt und 83.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.59% der Aktien des Unternehmens, im Wert von $3.31M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.1 Jahre bzw. 13.4 Jahre.

Wichtige Informationen

Laura Francis

Geschäftsführender

US$3.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	16.8%
Amtszeit als Geschäftsführer	3.2yrs
Eigentum des Geschäftsführers	0.6%
Durchschnittliche Amtszeit des Managements	3.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	13.5yrs

Jüngste Management Updates

Recent updates

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

Apr 01

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Feb 29

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Laura Francis im Vergleich zu den Einnahmen von SI-BONE verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$43m
Dec 31 2023	US$4m	US$622k	-US$43m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$55m
Dec 31 2022	US$5m	US$604k	-US$61m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$3m	US$527k	-US$57m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$2m	US$386k	-US$44m
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$2m	US$375k	-US$38m
Sep 30 2019	n/a	n/a	-US$35m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$734k	US$319k	-US$17m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$21m
Dec 31 2017	US$518k	US$302k	-US$23m

Vergütung im Vergleich zum Markt: LauraDie Gesamtvergütung ($USD3.71M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.49M).

Entschädigung vs. Einkommen: LauraDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Laura Francis (57 yo)

3.2yrs

Amtszeit

US$3,713,871

Vergütung

Ms. Laura A. Francis, MBA, serves as Chief Executive Officer and Director at SI-BONE, Inc. since April 18, 2021. She was Chief Financial Officer of SI-Bone Inc. since May 26, 2015 until April 18, 2021 and...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Laura Francis	CEO & Director	3.2yrs	US$3.71m	0.59% $ 3.2m
Anshul Maheshwari	Chief Financial Officer	3.2yrs	US$1.86m	0.14% $ 790.5k
Anthony Recupero	President of Commercial Operations	7.9yrs	US$2.06m	0.21% $ 1.2m
Jeff Bertolini	Senior Vice President of Operations & Information Technology	1.9yrs	keine Daten	keine Daten
Scott Yerby	Senior VP of Engineering & CTO	no data	keine Daten	keine Daten
Saqib Iqbal	Director of FP&A and Investor Relations	no data	keine Daten	keine Daten
Michael Pisetsky	Chief Business & Legal Affairs Officer	7.8yrs	keine Daten	0.13% $ 712.9k
Aimee Einstein	Vice President of People & Culture	2.4yrs	keine Daten	keine Daten
Daniel Cher	Senior Vice President of Clinical & Regulatory Affairs	3yrs	keine Daten	keine Daten
W. Reckling	Chief Medical Officer & VP of Medical Affairs	no data	keine Daten	keine Daten
Nikolas Kerr	Senior Vice President of Product	3.2yrs	keine Daten	keine Daten
Troy Wahlenmaier	Senior Vice President of US Sales	less than a year	keine Daten	keine Daten

3.2yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: SIBNDas Führungsteam des Unternehmens gilt als erfahren (3.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Laura Francis	CEO & Director	3.2yrs	US$3.71m	0.59% $ 3.2m
Timothy Davis	Lead Independent Director	16.2yrs	US$211.30k	0.094% $ 512.7k
Gregory Hinckley	Independent Director	13.4yrs	US$191.30k	0.38% $ 2.1m
Jeryl Hilleman	Independent Director	4.5yrs	US$206.30k	0.025% $ 139.2k
John Freund	Independent Director	11.4yrs	US$188.30k	0.30% $ 1.7m
Keith Valentine	Independent Director	8.8yrs	US$191.30k	0.13% $ 695.1k
Ralph Rashbaum	Member of Medical Advisory Board	14.4yrs	keine Daten	keine Daten
Steven Garfin	Member of Medical Advisory Board	14.4yrs	keine Daten	keine Daten
Frank Phillips	Member of Medical Advisory Board	14.4yrs	keine Daten	keine Daten
Jeffrey Dunn	Executive Chairman	16.2yrs	US$551.18k	0.25% $ 1.4m
A. Shamie	Member of Medical Advisory Board	13.5yrs	keine Daten	keine Daten
Jonathan Hyde	Member of Surgeon Advisory Board	no data	keine Daten	keine Daten

13.5yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: SIBNDie Vorstandsmitglieder sind sehr erfahren ( 13.4 ).

SI-BONE Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

CEO & Director recently sold US$809k worth of stock

Lead Independent Director notifies of intention to sell stock

Executive Chairman recently sold US$141k worth of stock

Executive Chairman exercised options and sold US$337k worth of stock

Recent updates

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

New minor risk - Profitability

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2026

CEO & Director recently sold US$809k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Lead Independent Director notifies of intention to sell stock

Executive Chairman recently sold US$141k worth of stock

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Price target decreased by 7.3% to US$28.38

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Executive Chairman exercised options and sold US$337k worth of stock

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

Executive Chairman notifies of intention to sell stock

CEO & Director recently sold US$189k worth of stock

Executive Chairman notifies of intention to sell stock

Independent Director recently sold US$616k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold US$224k worth of stock

President of Commercial Operations notifies of intention to sell stock

Executive Chairman exercised options and sold US$5.1m worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Key Executive notifies of intention to sell stock

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 16% to US$24.50

President of Commercial Operations notifies of intention to sell stock

CEO & Director recently sold US$226k worth of stock

Executive Chairman notifies of intention to sell stock

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Price target decreased to US$22.38

Executive Chairman recently sold US$105k worth of stock

CEO & Director notifies of intention to sell stock

Third quarter 2022 earnings: EPS exceeds analyst expectations

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Executive Chairman recently sold US$138k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite

Chief Financial Officer recently sold US$52k worth of stock

Consensus forecasts updated

Price target decreased to US$28.71